These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27168275)

  • 21. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
    Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA
    Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
    Ivanic MG; Thatiparthi A; Walia S; Liao W; Wu JJ
    J Drugs Dermatol; 2021 Aug; 20(8):837-843. PubMed ID: 34397197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
    Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
    [No Abstract]   [Full Text] [Related]  

  • 31. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Nov; 79(5):953-956. PubMed ID: 29730366
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of Common Side Effects of Apremilast.
    Langley A; Beecker J
    J Cutan Med Surg; 2018; 22(4):415-421. PubMed ID: 29290125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effects of Apremilast Therapy on Deployability in Active Duty US Army Soldiers With Plaque Psoriasis and Psoriatic Arthritis.
    Price AD; Wagler VD; Donaldson C; Mastin PJ
    J Clin Rheumatol; 2021 Apr; 27(3):127-128. PubMed ID: 33136692
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe bitter taste associated with apremilast.
    Damiani G; Bragazzi NL; Grossi E; Petrou S; Radovanovic D; Rizzi M; Atzeni F; Sarzi-Puttini P; Santus P; Pigatto PD; Franchi C
    Dermatol Ther; 2019 May; 32(3):e12876. PubMed ID: 30882959
    [No Abstract]   [Full Text] [Related]  

  • 38. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report.
    Rathod D; Weinberg JM; Yamauchi PS; Kircik LH; Wollina U; Lotti T; Goldust M
    J Drugs Dermatol; 2019 Apr; 18(4):394-396. PubMed ID: 31017383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.